RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancerAccording to an October 2023 paper in the Oncologist regarding the ' Evolving Landscape of Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in the Treatment of Early Breast Cancer ' various novel modalities of immunotherapy, including CAR-T cell therapy, bispecific T-cell engagers, and other immunomodulatory receptors like LAG-3 have been evaluated in patients with breast cancer, particularly in the metastatic setting. Oncolytic virus therapy is one of the few modalities that has shown promising therapeutic efficacy in early-stage breast cancer."
https://academic.oup.com/oncolo/article/28/10/832/7246404